Kenneth Mulvany
- n
- D
Appointment to the Board
May 2024
Skills and experience
Kenneth is a founder of BenevolentAI and was the company’s Chairman from its 2013 foundation until July 2021.
Before establishing BenevolentAI, he was the CEO of Proximagen Group plc, a leading biotech firm specialising in the development of medicines to treat neurodegeneration. Proximagen was sold to Upsher-Smith for a headline value of US$553 million. In addition to leading innovative companies, Kenneth has proactively served on several advisory boards, including the UK Government advisory board on AI strategies and the Oxford Sciences Innovations advisory board.
Kenneth has also dedicated efforts to philanthropy and was Chair of the Trustees for the Cure Parkinson’s Trust between 2013 and 2018.